Overdosage in humans may result in a prolonged duration of action. In case of overdose, Orgalutran treatment should be (temporarily) discontinued.
No data on acute toxicity of Orgalutran in humans are available but it is unlikely that toxic effects will occur. Clinical studies with subcutaneous administration of Orgalutran at single doses up to 12 mg did not show systemic undesirable effects. In acute toxicity studies in rats and monkeys non-specific toxic symptoms were only observed after intravenous administration of ganirelix over 1 and 3 mg/kg, respectively.